Platelet-activating factor acetylhydrolase and premature ovarian failure

被引:0
作者
Chen, Hui [1 ]
Xiao, Xue [1 ]
Shan, Dan [1 ]
Li, Wenjuan [1 ]
Liao, Yanbiao [1 ]
Xu, Liangzhi [1 ]
机构
[1] West China Second Hosp, Dept Obstet & Gynecol, Chengdu, Peoples R China
关键词
Premature ovarian failure (POF); Platelet-activating factor (PAF); PAF acetylhydrolase (PAF-AH); PHOSPHOLIPASE A(2); DISEASE; RISK; INFLAMMATION; LDL;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Premature ovarian failure (POF) appears to be a complex disease entity with several underlying etiopathogenic contributions including the possibility of multiple distinctly different autoimmune mechanisms, in which inflammatory autoimmunity targeted to ovarianspecific germline antigens (e.g., zona pellucida proteins or Mater) or differentiation/regulatory factors (e.g. inhibin-alpha) were regarded as one of the most crucial factors. Platelet-activating factor (PAF) and PAF class oxidized phospholipids stimulate the occurrence and development of inflammation and atherosclerosis. PAF acetylhydrolase (PAF-AH) can hydrolyze PAF and PAF class oxidized phospholipids and eventually prevent the body from the damage of these inflammatory mediators. These findings indicate a potential relationship between PAF-AH and POF thus have major implications for the future health of women who suffer with premature ovarian failure.
引用
收藏
页码:613 / 616
页数:4
相关论文
共 21 条
[1]   Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe [J].
Abuzeid, AM ;
Hawe, E ;
Humphries, SE ;
Talmud, PJ .
ATHEROSCLEROSIS, 2003, 168 (02) :283-288
[2]   Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease [J].
Caslake, MJ ;
Packard, CJ .
CURRENT OPINION IN LIPIDOLOGY, 2003, 14 (04) :347-352
[3]   Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J].
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
FERTILITY AND STERILITY, 2004, 81 (01) :19-25
[4]   Platelet-activating factor acetylhydrolase: is it good or bad for you? [J].
Chen, CH .
CURRENT OPINION IN LIPIDOLOGY, 2004, 15 (03) :337-341
[5]   RISK-FACTORS FOR CORONARY-ARTERY DISEASE IN LEAN AND OBESE WOMEN WITH THE POLYCYSTIC-OVARY-SYNDROME [J].
CONWAY, GS ;
AGRAWAL, R ;
BETTERIDGE, DJ ;
JACOBS, HS .
CLINICAL ENDOCRINOLOGY, 1992, 37 (02) :119-125
[6]   MEDICAL PROGRESS - POLYCYSTIC-OVARY-SYNDROME [J].
FRANKS, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (13) :853-861
[7]   Editorial: Cardiovascular risk in PCOS [J].
Guzick, DS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08) :3694-3695
[8]   Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study) [J].
Hulthe, J ;
Fagerberg, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (07) :1162-1167
[9]   Plasma platelet activating factor-acetylhydrolase (PAF-AH) [J].
Karasawa, K ;
Harada, A ;
Satoh, N ;
Inoue, K ;
Setaka, M .
PROGRESS IN LIPID RESEARCH, 2003, 42 (02) :93-114
[10]   Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome [J].
Khovidhunkit, W ;
Memon, RA ;
Shigenaga, JK ;
Pang, M ;
Schambelan, M ;
Mulligan, K ;
Feingold, KR ;
Grunfeld, C .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (12) :1524-1531